Who we are?

CREATOR: gd-jpeg v1.0 (using IJG JPEG v62), quality = 82
Founder & CEO

Helle Funch Nielsen

Linkedin Envelope
About

Helle is the Chief Executive Officer and founder of Exhalation Technology, which she established in 2003 to develop breath-based diagnostics for airway inflammation in horses. In 2014, she shifted the company’s focus to human health, where it is now pioneering point-of-care breath analysis for earlier disease detection.

She brings broad pharmaceutical experience from senior roles at Fisons, Rhône Poulenc Rorer, Alcon, and Galderma, working with asthma, allergy, and dermatology products. Helle also founded Equine Healthcare ApS, where she developed leading inhalation and nebuliser devices for equine asthma, underscoring her track record in translating innovation into practical healthcare solutions.

john devrill exhalation technology
Executive Chairman of the Board

John Deverill

Linkedin Envelope
About

John is the Executive Chairman of the Board at Exhalation Technology, bringing over 25 years of experience in MedTech and healthcare. A former army officer and qualified engineer, he has held senior roles at GE Healthcare, boutique consultancies, large corporates, and within the NHS.

He has led strategic partnerships across Europe, the Middle East, and Africa, and advised on system transformation and market access. At Exhalation Technology, John guides the company’s strategic direction and growth while also serving as chair and non-executive director within the NHS.

CREATOR: gd-jpeg v1.0 (using IJG JPEG v62), quality = 82
CTO

Stig Lytke Brejl

Linkedin Envelope
About

Stig is the Chief Technology Officer at Exhalation Technology, where he has been a key member of the team since 2012. He has shaped the company’s strategic direction while gaining extensive hands-on experience in MedTech product development, quality assurance, and regulatory approval.

With nearly 35 years of professional experience, Stig has held senior management roles across multiple industries and worked internationally as a management consultant, advising on growth, operations, and transformation. He holds an MSc in Mechanical Engineering and a business degree from Copenhagen Business School, combining technical expertise with commercial insight to drive Exhalation

Advisor to the Board

Dr. Graham Clarke

Linkedin
About

Graham is a proven R&D leader with 20+ years of experience de-risking pipelines, accelerating development, and driving asset differentiation across pharma, biotech, and med tech. At AstraZeneca, he built the company’s early precision medicine infrastructure—advancing biomarker-driven trials, patient stratification, and strategic CRO alliances across Immunology and Respiratory portfolios.

Previously VP at hVIVO and Head of Respiratory early clinical development at IQVIA, he launched innovative Phase 1/2 services and led validation of novel biomarker platforms, including breath and airway sampling diagnostics.

He holds a PhD from King’s College London, where he is also Visiting Professor, and lectures widely on precision medicine and R&D strateg

Finance Director

Martyn Pitman

Linkedin Envelope
About

Martyn has been Finance Director at Exhalation Technology since 2019 through the FD & CFO Centre, bringing extensive experience in financial leadership and business growth. He is a Chartered Accountant with a background in healthcare, consultancy, and the military.

Previously, he was Commercial Finance Director at Moorfields Eye Hospital, where he strengthened financial strategy in a complex clinical environment. Earlier, he served in the Royal Air Force before qualifying with a Big Four firm in London and Ottawa. At Exhalation Technology, Martyn ensures robust financial discipline and investment readiness as the company advances its breath-based diagnostic platform.